Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Dr. Reddy’s Laboratories Ltd. ADR shares valued at $5,390,000 were purchased by Israeli Erez on Jul 29 ’24. At $82.29 per share, Israeli Erez acquired 65,500 shares.
As published in a research note from Nomura on December 19, 2024, Dr. Reddy’s Laboratories Ltd. ADR [RDY] has been rated down from a Buy to a Neutral. Analysts at Jefferies downgraded the stock from ‘”a Buy”‘ to ‘”an Underperform”‘ outlook in a report released in mid January. As of August 29, 2023, HSBC Securities has decreased its “Buy” rating to a “Hold” for RDY. Earlier on May 18, 2023, Bernstein downgraded its rating. Their new recommendation was “a Mkt perform” for RDY stock which previously was a “an Outperform”.
Analyzing RDY Stock Performance
During the last five days, there has been a surge of approximately 0.94%. Over the course of the year, Dr. Reddy’s Laboratories Ltd. ADR shares have dropped approximately -11.72%. Shares of the company reached a 52-week high of $15.84 on 01/07/25 and a 52-week low of $13.36 on 01/28/25. A 50-day SMA is recorded $14.68, while a 200-day SMA reached $15.14. Nevertheless, trading volume fell to 1.83 million shares from 1.4 million shares the previous day.
Support And Resistance Levels for Dr. Reddy’s Laboratories Ltd. ADR (RDY)
According to the 24-hour chart, there is a support level at 13.87, which, if violated, would cause prices to drop to 13.81. In the upper region, resistance lies at 14.02. The next price resistance is at 14.11. RSI (Relative Strength Index) is 40.54 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.13, which suggests the price will decrease in the coming days. Percent R is at 66.57%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
